Scholar Rock SRRK Early Research — Research And Development Expense

Other product segments

Similar metrics at other companies

DNTHDiscovery Expenses — Research And Development Expense

$1.36M+51.4%

DNTHOther Costs — Research And Development Expense

$1.49M+25.5%

DNTHPersonnel And Related Costs — Research And Development Expense

$8.64M+47.7%

LLYEarly-stage — R&D

$1.27B+27.9%

TRA

TRAXPreclinical And Other Unallocated Costs — Research And Development Expense Reversal Excluding Acquired In Process Cost

$3.3M-16.2%

TNGXPersonnel-Related Expenses-RD — Research And Development Expense

$12.93M-6.6%

Questions, answered.

What is Scholar Rock's early research — research and development expense?

Scholar Rock (SRRK) reported early research — research and development expense of $1.21M in Q1 2026.

How has Scholar Rock's early research — research and development expense changed year-over-year?

Scholar Rock's early research — research and development expense decreased by 16.8% year-over-year, from $1.46M to $1.21M.

What is the long-term trend for Scholar Rock's early research — research and development expense?

Over 2 years (2023 to 2025), Scholar Rock's early research — research and development expense has grown at a 22.3% compound annual growth rate (CAGR), from $4.46M to $6.68M.

What does early research — research and development expense mean?

This metric represents the total operating costs specifically allocated to the discovery and preclinical development activities within the early-stage research segment. It captures the investment in scientific exploration, target validation, and initial drug candidate characterization before a program advances to formal clinical trials. Monitoring this expenditure provides insight into the company's commitment to building its long-term pipeline and the intensity of its innovation efforts.